Silverback Therapeutics Company Insiders

SPRY Stock   14.29  1.27  9.75%   
Silverback Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Silverback Therapeutics suggests that vertually all insiders are panicking. Silverback Therapeutics employs about 24 people. The company is managed by 11 executives with a total tenure of roughly 56 years, averaging almost 5.0 years of service per executive, having 2.18 employees per reported executive.

Silverback Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2025-01-06Laura ShawverDisposed 50000 @ 11.1View
2024-12-17Sarina TanimotoDisposed 100000 @ 11.67View
2024-12-13Justin ChakmaDisposed 27272 @ 12.06View
2024-12-12Brian DorseyDisposed 25000 @ 12.3View
2024-12-10Sarina TanimotoDisposed 100000 @ 13.16View
2024-12-06Justin ChakmaDisposed 50000 @ 14.23View
2024-12-04Laura ShawverDisposed 14772 @ 13.75View
2024-12-03Justin ChakmaDisposed 45000 @ 13.19View
2024-12-02Laura ShawverDisposed 97244 @ 13.56View
2024-11-27Justin ChakmaDisposed 25000 @ 14.39View
2024-11-25Justin ChakmaDisposed 32814 @ 14View
2024-11-11James E FlynnDisposed 528456 @ 18.04View
2024-10-16Kathleen D ScottDisposed 12500 @ 16View
2024-10-15Sarina TanimotoDisposed 100000 @ 14.88View
2024-10-08Richard E LowenthalDisposed 100000 @ 13.83View
2024-09-18Eric KarasDisposed 10000 @ 14View
2024-09-17Richard E LowenthalDisposed 100000 @ 12.93View
2024-08-26Peter A ThompsonDisposed 83695 @ 13View
2024-08-23Peter A ThompsonDisposed 69500 @ 13.03View
2024-08-21Peter A ThompsonDisposed 407700 @ 13.56View
Monitoring Silverback Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silverback Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Silverback Stock please use our How to Invest in Silverback Therapeutics guide.

Silverback Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.1623) % which means that it has lost $0.1623 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2241) %, meaning that it created substantial loss on money invested by shareholders. Silverback Therapeutics' management efficiency ratios could be used to measure how well Silverback Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.22 in 2025. Return On Capital Employed is likely to rise to -0.32 in 2025. At this time, Silverback Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 329.5 M in 2025, whereas Total Assets are likely to drop slightly above 136 M in 2025.
Common Stock Shares Outstanding is likely to rise to about 115 M in 2025, despite the fact that Net Loss is likely to grow to (29.7 M).

Silverback Therapeutics Workforce Comparison

Silverback Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 1,008. Silverback Therapeutics holds roughly 24.0 in number of employees claiming about 2.38% of equities under Health Care industry.

Silverback Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Silverback Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Silverback Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Silverback Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
5.0
10
2
 3,126,300 
 100,000 
2024-12-01
0.2927
24
82
 721,827 
 3,254,226 
2024-09-01
0.0893
5
56
 112,500 
 3,329,754 
2024-06-01
0.4
18
45
 2,331,868 
 8,303,518 
2024-03-01
0.2727
12
44
 5,161,299 
 606,320 
2023-09-01
0.8947
17
19
 7,836,258 
 599,910 
2023-06-01
1.4167
17
12
 4,760,000 
 4,600,000 
2022-12-01
2.0
2
1
 3,009,678 
 43,896 

Silverback Therapeutics Notable Stakeholders

A Silverback Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Silverback Therapeutics often face trade-offs trying to please all of them. Silverback Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Silverback Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
MD MBACoFounder OfficerProfile
Kathleen CPAChief OfficerProfile
Alexander EsqChief SecretaryProfile
Daniel RelovskySenior MarketingProfile
Eric KarasChief OfficerProfile
Justin ChakmaChief SecretaryProfile
Brian MSSVP ManagementProfile
MBA MBAEx StrategyProfile
Robert BellCoFounder OfficerProfile
Harris MBAExecutive StrategyProfile
MBA MSPresident, FounderProfile

About Silverback Therapeutics Management Performance

The success or failure of an entity such as Silverback Therapeutics often depends on how effective the management is. Silverback Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Silverback management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Silverback management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.21)(0.22)
Return On Capital Employed(0.34)(0.32)
Return On Assets(0.21)(0.22)
Return On Equity(0.27)(0.26)
Please note, the imprecision that can be found in Silverback Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Silverback Therapeutics. Check Silverback Therapeutics' Beneish M Score to see the likelihood of Silverback Therapeutics' management manipulating its earnings.

Silverback Therapeutics Workforce Analysis

Traditionally, organizations such as Silverback Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Silverback Therapeutics within its industry.

Silverback Therapeutics Manpower Efficiency

Return on Silverback Therapeutics Manpower

Revenue Per Employee1.2K
Revenue Per Executive2.7K
Net Loss Per Employee2.3M
Net Loss Per Executive4.9M
Working Capital Per Employee9.6M
Working Capital Per Executive20.8M

Additional Tools for Silverback Stock Analysis

When running Silverback Therapeutics' price analysis, check to measure Silverback Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silverback Therapeutics is operating at the current time. Most of Silverback Therapeutics' value examination focuses on studying past and present price action to predict the probability of Silverback Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silverback Therapeutics' price. Additionally, you may evaluate how the addition of Silverback Therapeutics to your portfolios can decrease your overall portfolio volatility.